Can Chocolate be Good for You? The Dark and Light Side of the Force
By Jesica Levingston Mac leod, PhD
It is this time of the year again: World chocolate day – the best excuse to give and more importantly to EAT a lot of chocolate. But, maybe a better gift that receiving chocolate, is to know that eating chocolate might be good for your health.
In the beginning chocolate was “created” as a medicine – a healthy beverage – around 1900 BC by Mesoamerican people. The Aztecs and Mayas gave it the name of “xocolatl”, it means bitter water, as the early preparations of the cacao seeds had an intense bitter taste. Almost one year ago, a longitudinal study, done in the US East Coast, connected eating chocolate with better cognitive function. Yay! Great news, right? The scientists gathered information over a period of 30 years (starting in 1976) from 968 subjects (aged 23-98 years) in the Syracuse-Maine area. The results showed that more frequent chocolate consumption was meaningfully associated with better performance on the global composite score, visual-spatial memory and organization, working memory, scanning and tracking, abstract reasoning, and the mini-mental state examination. Importantly, they pointed out that with the exception of working memory, these relations were not attenuated with statistical control for cardiovascular, lifestyle and dietary factors across the participants.
More good news arrived last summer: an Italian research team announced that flavanol-rich chocolate improves arterial function and working memory performance counteracting the effects of sleep deprivation. The researchers investigated the effect of flavanol-rich chocolate consumption on cognitive skills and cardiovascular parameters after sleep deprivation in 32 healthy participants, who underwent two baseline sessions after one night of undisturbed sleep and two experimental sessions after one night of total sleep deprivation. Two hours before each testing session, participants were assigned to consume high or poor flavanol chocolate bars. During the tests the participants were evaluated by the psychomotor vigilance task and a working memory task, systolic blood pressure (SBP) and diastolic blood pressure (DBP), flow-mediated dilation and pulse-wave velocity. As you might know, sleep deprivation increased SBP/DBP. The result was that SBP/DBP and pulse pressure were lower after flavanol-rich treatment respect to flavanol-poor treatment sleep deprivation impaired flow-mediated dilation, flavanol-rich, but not flavanol-poor chocolate counteracted this alteration. Flavanol-rich chocolate mitigated the pulse-wave velocity increase. Also, flavanol-rich chocolate preserved working memory accuracy in women after sleep deprivation. Flow-mediated dilation correlated with working memory performance accuracy in the sleep condition.
The European Food Safety Authority accepted the following statement for cocoa products containing 200 mg of flavanols: “cocoa flavanols help maintain the elasticity of blood vessels, which contributes to normal blood flow”. This statement means that flavanol-rich chocolate counteracted vascular impairment after sleep deprivation and restored working memory performance. In another study led by Columbia University Medical Center scientists, dietary cocoa flavanols—naturally occurring bioactives found in cocoa—reversed age-related memory decline in healthy older adults. One possibility is that the improvement in cognitive performance could be due to the effects of cocoa flavonoids on blood pressure and peripheral and central blood flow. Following on this other chocolate attribute, it was shown than weekly chocolate intake may be beneficial to arterial stiffness.
But, there are some bad news! A review of 13 scientific articles on this topic, provided evidence that dark chocolate did not reduce blood pressure. However, the reviewers claimed that there was an association with increased flow-mediated vasodilatation (FMD) and moderate for an improvement in blood glucose and lipid metabolism. Specifically, their analysis showed that chocolates containing around 100 mg epicatechin can reliably increase FMD, and that cocoa flavanol doses of around 900 mg or above may decrease blood pressure if consumed over longer periods: “Out of 32 cocoa product samples analyzed, the two food supplements delivered 900 mg of total flavanols and 100 mg epicatechin in doses of 7 g and 20 g and 3 and 8 g, respectively. To achieve these doses with chocolate, you will need to consume 100 to 500 g (for 900 mg flavanols) and 50 to 200 g (for 100 mg epicatechin). Chocolate products marketed for their purported health benefits should therefore declare the amounts of total flavanols and epicatechin”. The method of manufacturing dark chocolate retains epicatechin, whereas milk chocolate does not contain substantial amounts of epicatechin.
The first epidemiological “indication” for beneficial health effects of chocolate were found in Kuna natives in Panama with low prevalence of atherosclerosis, type 2 diabetes, and hypertension. This fact correlated with their daily intake of a homemade cocoa. These traits disappear after migration to urban and changes in diet.
There are many claims about the potential health benefits of chocolate, including anti-oxidative effect by polyphenols, anti-depressant effect by high serotonin levels, inhibition of platelet aggregation and prevention of obesity-dependent insulin resistance. Chocolate contains quercetin, a powerful antioxidant that protects cells against damage from free-radicals. Chocolate also contains theobromine and caffeine, which are central nervous system stimulants, diuretics and smooth muscle relaxants, and valeric acid, which is a stress reducer. However, chocolate also contains sugar and other additives in some chocolate products that might not be so good for your health.
Oh well, maybe the love of chocolate is like any other romantic affair: blind and passionate. Apparently, the beneficial dosage is 10 g of dark chocolate per day (>70% cocoa), so enjoy it as long as the serotonin boost for rewarding yourself with a new treat last.
Happy world chocolate day!
Showing posts with label womeninscience. Show all posts
Showing posts with label womeninscience. Show all posts
Saturday, July 7, 2018
Friday, May 2, 2014
Pathways for Science Careers in the Cosmetics Industry
MetroNY AWIS invites you to our upcoming event:
Panel Discussion and Networking event on Science in the the Cosmetics Industry
May 8th, 6:30-8:30 pm
Register at http://www.meetup.com/MetroNY-AWIS-Meetup-Group/events/166156842/
Pathways for Science Careers in the Cosmetics Industry
Join us for a career panel and networking event featuring a diverse panel of scientific experts from cosmetic and personal care companies featuring remarks from David Smith, Executive Director of the Society of Cosmetic Chemists. Learn how scientific expertise is used in the cosmetic and personal care industry and explore career opportunities and factors that lead to success in these industries.
Christina Andrianov, M.A. (R&D Manager at Mast Global Technical Service,Limited Brands), Marianne Mota Paulino, M.S.(Senior Process Engineer at L’Oreal), Alisa Vasilenko, Ph.D. (Manager of Luxury Development at L’Oreal) and Dulce Almario, M.S., (Director of Product Innovations at Victoria Secret Beauty) will present in a panel discussion.
The Panel will be moderated by Amanda Weyerbacher, Ph.D., who has worked as a Senior Scientist in the Product Safety and Toxicology Department at L’Oreal USA Research and Innovation.
We look forward to seeing you there!
Please note: this is not a job fair featuring employers.
About the speakers:
Marianne Mota Paulino started her career with L’Oreal USA in 2009 as a formulation chemist of hair styling products. In 2012, she transferred to her current role in the pilot team where she is in charge of developing efficient processes for the hair category. As a Sr. Process Engineer, she also ensures technology scale-up and the successful manufacturing of new product launches. Prior to this position, she earned her M.S. in Chemical Engineering at Carnegie Mellon University, where she studied the release of PEGylated proteins from PLG microspheres. She also worked as an intern in 3M and Procter and Gamble (P&G), where she had the opportunity to work on the development of new industrial adhesives and consumer studies for sanitary napkins, respectively. She obtained her dual B.S. in Chemistry and Chemical Engineering from University of Florida in 2006.
Christina Andrianov has over 15 years of experience in the Cosmetic Personal Care Industry. She has worked for Mast Global Tech Services since January 2006. As an R&D Manager, she oversees all personal care product development for Victoria Secret Beauty. She manages a team of chemist to ensure a wide variety of formulas meet marketing expectations for aesthetics and meet the stringent timelines. Her team also has to ensure the
formulas are compliant with global regulations and are reproducible on larger scale. Prior to this position, Mrs. Andrianov worked at Ciba Specialty Chemicals (today known as BASF) in the Personal Care Division researching to see if various technologies from different departments could be transferred and applied to Personal Care products. She has also worked for other companies like Outsourcing Services Group, L’Oreal USA – the Maybelline division, Estee Lauder – Clinique Treatment Lab. She earned her M.A. in Cosmetic Science from Fairly Dickinson University, Teaneck NJ in 2003, B.S in Chemistry from SUNY at Stony Brook, NY in 1994.
The panel moderator, Amanda Weyerbacher, previously worked as in Senior Scientist in the Product safety department at L’Oreal. In this role, she managed the clinical safety testing program of multiple consumer products across a wide array of global brands for market launch, ensuring compliance with international regulatory requirements and claim substantiation. Prior to
this position, Dr. Weyerbacher earned her Ph.D. in Pharmacology at Cornell University’s - Weill Cornell Graduate School of Biological Sciences in New York City in May 2009. In her dissertation research, she identified critical pain signaling proteins, cytokines and immune/
central nervous system interactions as relevant drug targets for clinical pain control in an animal model of persistent pain. From 2001-2003, Dr. Weyerbacher was a Clinical Research Associate at Memorial Sloan Kettering Cancer Center. In this role, she managed up to ten active Phase I and II clinical trials, defining and monitoring project scope, timelines and deliverables from project initiation to close-out. She earned her B.A. in Biology-Chemistry from Skidmore College in Saratoga Springs, NY in May 2001.
--
The MetroNY AWIS Team
Website: http://metronyawis.weebly.com/
Email: metronyawis@gmail.com
twitter: @MetroNYAWIS
AWIS is a national advocacy organization championing the interests of women in science across all disciplines and employment sectors.
Not a member? Join now!
http://www.awis.affiniscape.com/displaycommon.cfm?an=1&subarticlenbr=293
Students: Contact metronyawis@gmail.com with subject heading 'membership' and attach an image of your student photoID
Subscribe to:
Posts (Atom)